Clinical Research Directory
Browse clinical research sites, groups, and studies.
DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer
Sponsor: Mahidol University
Summary
This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer. Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure. The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.
Official title: DOminant-TArgeted Stereotactic Ablative Radiotherapy in Localized Prostate Cancer: Single-fraction Phase I/II Pilot Study (DOTA-1)
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-06-02
Completion Date
2033-06
Last Updated
2026-11-20
Healthy Volunteers
No
Conditions
Interventions
Single-fraction MR-guided SBRT 20 Gy with simultaneous integrated boost to the dominant intraprostatic lesion 26 Gy
A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.
Locations (1)
Siriraj Hospital
Bangkok Noi, Bangkok, Thailand